Updates in hematology/ oncology

Do you know the most frequent clinical manifestation in multiple myeloma?

The answer to this question goes this way.......

The clinical manifestations in multiple myeloma generally be

• Anemia: 73%
• Osteolytic bone lesions: 67%
• Bone pain: 58%
• Kidney Failure: 48%
• Hypercalcemia: 28%

So, the most frequent manifestation in multiple myeloma is anemia.

To know more interesting updates in hematology and oncology, join us at, PS: World Hematology 2020

World Hematology 2020

We have our speaker slots open. Submit your abstracts now and avail early bird offers on registration. We offer special group registration benefits. To know more, PS: https://hematology.cmesociety.com/

World Hematology 2020

Come and Join us in Scotland to witness the gathering of experts in hematology & oncology, this March 2- 3, 2020. More info, PS: https://hematology.cmesociety.com/

#hematology #leukemia #lymphoma #cancer #oncology #Conference #events #meetings #Congress #conferences #AML #Blood #anemia #MDS

World Hematology 2020

Join us at the leading and largest conference on hematology & oncology in Edinburgh, Scotland, this March 2020. Submit your abstracts now & avail early bird offers in registration! For more info, PS: https://hematology.cmesociety.com/abstract-submission

Recent updates in hematology & oncology

Trials show, azacitidine & pembrolizumab combination is safe, feasible and well-tolerated for relapsed and refractory AML. Explore more trends in hematology & oncology at: https://hematology.cmesociety.com 

Recent updates in hematology/ oncology

According to new guidelines on venous thromboembolism (VTE) from ASH, pharmacologic prophylaxis is not recommended for patients experiencing major trauma deemed to be at high risk of bleeding.

David R. Anderson, MD, dean of the faculty of medicine at Dalhousie University stated that while pharmacologic prophylaxis reduce the risk of symptomatic pulmonary embolism and deep vein thrombosis by about 10 events per 1,000 patients, the increased risk of major bleeding (24 events per 1,000 patients) outweighs the benefits.

When pharmacologic prophylaxis is used, the panel recommends combined prophylaxis – mechanical prophylaxis in addition to pharmacologic prophylaxis – especially in those patients at high or very high risk of VTE. Evidence shows that the combination approach significantly reduces risk of PE, and strongly suggests it may also reduce risk of symptomatic proximal DVT.

Explore and discuss more recent updates in the field of hematology and oncology with us. Join us in Scotland, this March. Know more information at, PS: World Hematology 2020

Source: https://www.mdedge.com/hematology-oncology/quiz/8776/fast-facts-friday/fast-facts-friday-december-13-2019?channel=59610

Recent updates in hematology/ oncology

Trials show that, children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia reported sustained, clinically meaningful improvement in quality-of-life scores after receiving chimeric antigen receptor T-cell therapy. To know more such updates, join us at: http://tiny.cc/9t8ybz